Back

A time-dependent analysis of sacubitril/valsartan and gliflozins benefits in patients receiving cardiac resynchronization therapy

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Cardiac resynchronisation therapy - conduction system pacing 1 Cardiac Resynchronisation Therapy (CRT) EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Daniele Faccenda

Istituto Cardiocentro Ticino, Lugan (Switzerland)

7 More presentations in this session

Presentation thumbnail
Electrocardiographic predictors of haemodynamic benefit from biventricular pacing: the role of atrioventricular timing measures
Doctor T. Chakraborty (London, GB) Doctor A. Arnold (London, GB)
Abstract Slides Video
Presentation thumbnail
CRT with triple fusion: results of the multicentric, randomized, doble-blinded CRUSTY trial.
Doctor J. Francisco Pascual (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
His bundle pacing implantation in octogenarian patients: a substudy of the PACE-CONDUCT trial
Doctor D. Stangl (Fuerth, DE)
Abstract Slides Video
Presentation thumbnail
Temporal evolution of His bundle pacing thresholds: a sub-study of the PACE-CONDUCT trial
Doctor V. Buia (Fuerth, DE)
Abstract Slides Video
Presentation thumbnail
Right ventricular systolic pressure is an independent risk factor of all-cause death and inappropriate therapies in patients with implanted CRT-D
Doctor J. Machowicz (Zabrze, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac resynchronisation therapy - conduction system pacing 1

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.
thumbnail
Congress Presentation
The additional value of sacubitril/valsartan in fusion pacing CRT
thumbnail
Congress Presentation
Comparing treatment strategies for heart failure: a real-world analysis of adding ARNI or SGLT2i to older GDMT

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources